a public good project by the
Synthesis
Company
of California

© 2026

Maeva Dufies | doi.page

0 works0 citations0 h-index

Maeva Dufies

Centre National de la Recherche Scientifique(FR)Inserm(FR)Institut de Recherche sur le Cancer et le Vieillissement de Nice(FR)Centre Antoine Lacassagne(FR)

Publications by Year

Research Areas

Renal cell carcinoma treatment, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Renal and related cancers, Polyamine Metabolism and Applications

Most-Cited Works

→ The Epithelial-Mesenchymal Transition (EMT) Regulatory Factor SLUG (SNAI2) Is a Downstream Target of SPARC and AKT in Promoting Melanoma Cell Invasion(2012)222 cited
→ Autophagy is required for CSF-1–induced macrophagic differentiation and acquisition of phagocytic functions(2012)148 cited
→ Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux(2015)138 cited
→ Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells(2011)118 cited
→ Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas(2017)112 cited
→ BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients(2012)82 cited

→ Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors(2009)81 cited

→ Synthesis and biological evaluation of 3-amino-1,2,4-triazole derivatives as potential anticancer compounds(2020)71 cited

→ Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC(2010)69 cited

→ Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma(2020)63 cited